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MLL rearrangements are translocation mutations that cause both acute lymphoblastic
leukemia and acute myeloid leukemia (AML). These translocations can occur as sole clonal
driver mutations in infant leukemias, suggesting that fetal or neonatal hematopoietic
progenitors may be exquisitely sensitive to transformation by MLL fusion proteins. To test
this possibility, we used transgenic mice to induce one translocation product, MLL-ENL,
during fetal, neonatal, juvenile and adult stages of life. WhenMLL-ENLwas induced in fetal
or neonatal mice, almost all died of AML. In contrast, when MLL-ENL was induced in adult
mice, most survived for.1 year despite sustained transgene expression. AML initiation was
most efficient when MLL-ENL was induced in neonates, and even transient suppression of
MLL-ENL in neonates could prevent AML inmost mice. MLL-ENL target genes were induced
more efficiently in neonatal progenitors than in adult progenitors, consistent with the
distinct AML initiation efficiencies. Interestingly, transplantation stress mitigated the
developmental barrier to leukemogenesis. Since fetal/neonatal progenitors were highly
competent to initiate MLL-ENL–driven AML, we tested whether Lin28b, a fetal master
regulator, could accelerate leukemogenesis. Surprisingly, Lin28b suppressed AML initiation
rather than accelerating it. This may explain why MLL rearrangements often occur before
birth in human infant leukemia patients, but transformation usually does not occur until
after birth, when Lin28b levels decline. Our findings show that the efficiency of MLL-
ENL–driven AML initiation changes through the course of pre- and postnatal development,
and developmental programs can be manipulated to impede transformation.
Introduction
Infant leukemias are clinically and genetically distinct from leukemias that present later in childhood or
in adulthood.1-3 They initiate prior to or shortly after birth, and they can present as either acute
lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).4,5 Unlike many other childhood
leukemias, infant leukemias are difficult to treat, and most infants die of their disease despite intense
chemotherapy.6-8 Approximately 40% of infants with AML and ;70% of infants with ALL harbor MLL
(KMT2A) rearrangements (eg, MLL-ENL, MLL-AF4, or MLL-AF9).2,8 These leukemias carry very few
additional mutations, and in some cases, the MLL rearrangement appears to be the sole clonal driver
mutation.3 MLL rearrangements are less common, relative to other mutations, in later childhood and
adult leukemias.2,3,9 In instances when they do occur in adults, the leukemias typically carry additional
cooperating mutations,3 and they often occur in patients who have received prior chemotherapy for
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other malignancies.10,11 Thus, the genetic changes that cause
leukemia in infants are distinct from changes that cause leukemia
in adults.
MLL encodes a SET-domain–containing histone 3, lysine 4 (H3K4)
methyltransferase that promotes expression of genes associated
with self-renewal (eg, MEIS1 and HOXA cluster genes).12-14 In
MLL-rearranged leukemias, the C terminus of the protein, including
the SET domain, is replaced with one of several potential fusion
partners (eg, ENL, AF4, AF9, and AF10).11,15 MLL fusion proteins
recruit the H3K79 methyltransferase DOT1L, and the H3K36
methyltransferase ASH1L, to MLL target loci as part of a multi-
protein complex.16-18 H3K79 and H3K36 dimethylation marks
correlate with active gene expression, and both Dot1l and Ash1l
are required for MLL-AF9–driven AML to develop in mice.17,18 In
addition to regulating histone methylation, MLL fusion proteins
nucleate a complex, called the superelongation complex, which
promotes transcriptional elongation.19,20 Through these biochem-
ical activities, MLL fusion proteins elicit epigenetic and transcrip-
tional changes that promote self-renewal and distinguish infant
leukemias from most other types of childhood and adult AML or
ALL.21-28
It is not clear why MLL rearrangements require so few cooperating
mutations to initiate infant leukemias. One possible explanation is
that fetal or neonatal hematopoietic progenitors may be inherently
more susceptible to transformation by MLL fusion proteins than
adult progenitors. Several lines of evidence support this hypothesis.
For example, prior studies have shown that human umbilical cord
blood progenitors can be immortalized more efficiently by MLL-
AF9–expressing lentiviruses than adult bone marrow progenitors.29
Furthermore, MLL-AF4 has been shown to induce B-cell pro-
liferation, and eventual lymphomagenesis, when it is induced in
fetal B-cell progenitors, but it does not cause lymphomas when it is
induced after birth.30 Finally, other leukemogenic mutations have
been shown to have developmental context-specific effects on self-
renewal and leukemia initiation. Pten loss of function and Flt3-
internal tandem duplication mutations deplete hematopoietic stem
cells (HSCs), expand committed progenitor populations, and cause
leukemia only in juvenile or adult developmental contexts.31,32 MLL
rearrangements may have a similar propensity to cause leukemia in
a fetal or neonatal context, particularly when they are expressed at
physiologic rather than supraphysiologic levels.
In the current study, we sought to identify the developmental stages
that are most permissive for MLL-ENL–driven leukemogenesis. We
found that MLL-ENL caused AML with the highest penetrance
(100%) and the shortest latency when it was induced in neonates
as compared with both fetal and adult mice. Even transient
suppression of MLL-ENL during the neonatal period was sufficient
to prevent leukemogenesis in most mice. MLL-ENL caused HSC
and lineage-committed hematopoietic progenitor cell (HPC) de-
pletion when it was induced in fetal/neonatal mice, but not when it
was induced in adult mice. Furthermore, MLL-ENL target genes
were activated more efficiently in neonatal progenitors than in adult
progenitors. Adult progenitors did give rise to AML with complete
penetrance when they were transplanted. These findings show
that leukemia initiation efficiency changes as developmental context
changes, but the barriers to transformation can be mitigated by
transplantation stress.
We tested whether a fetal master regulator, Lin28b, could
accelerate rates of AML initiation in MLL-ENL–expressing mice.
Lin28b is highly expressed in fetal HSCs and HPCs, but levels
decline in neonatal progenitors, both in mice and humans.32-34 To
our surprise, sustained Lin28b expression suppressed rather than
accelerated AML formation, suggesting that it may afford protection
from MLL rearrangements during fetal stages before its expres-
sion declines in neonates. This may explain why, in humans, MLL
rearrangements often occur prior to birth but overt leukemias do not
usually arise until after birth.4,5,35 Altogether, the data show that
MLL-ENL-mediated changes in gene expression and cell fate are
developmental stage-specific, and AML initiation efficiency peaks
during the neonatal stage of life. Mechanisms that define this
window of peak susceptibility can be manipulated to suppress
leukemogenesis.
Materials and methods
Mouse strains and husbandry
The Col1a1TetO_MLL-ENL line has been previously described.36
Vav1-Cre (008610),37 RosaLSL-tTA (011008),38 RosaLSL-rtTA-EGFP
(005670),39 andCol1a1TetO_H2B-GFP (016836)40 mice were obtained
from The Jackson Laboratory. Col1a1TetO_Lin28b mice were obtained
from Hao Zhu (UT-Southwestern) and are now available at The
Jackson Laboratory (023911).41 Doxycycline chow (200 ppm) was
purchased fromBioserv. All mouse strains were on a C57BL/6 genetic
background. Transplantations were performed as described pre-
viously.32 All animals were housed in a pathogen-free barrier facility,
and all procedures were performed according to an Institutional Animal
Care and Use Committee–approved protocol.
Flow cytometry
Bone marrow cells were obtained, stained, and analyzed as described
previously.32 Cell counts were measured by hemocytometer. Anti-
bodies are listed in supplemental Materials and methods. Flow
cytometry was performed on a BD FACSAria Fusion flow cytometer
(BD Biosciences). Bromodeoxyuridine (BrdU) incorporation assays
were performed with the APC BrdU Flow Kit (BD Biosciences)
according to manufacturer’s instructions as described previously.31 A
detailed protocol is provided in supplemental Materials and methods.
Leukemia analyses
Mice were euthanized when they became moribund. Spleens and
bone marrow were analyzed by flow cytometry with antibodies to
CD3, CD11b, Gr-1, and B220 to determine the leukemia type.
Spleen sections were stained with hematoxylin and eosin. Bone
marrow cells were isolated and spun onto glass slides using
a Shandon Cytospin 3. The slides were stained using Protocol
Hema 3 Wright-Giemsa stain (Fisher Scientific). CD3 immunohisto-
chemistry was performed with rat anti-CD3 (Bio-Rad, CD3-12) and
horseradish peroxidase–conjugated goat anti-rat immunoglobulin G
(BioLegend). Sections were developed with the DAB peroxidase
substrate kit (Vector Labs) according to manufacturer protocols.
Lentivirus transductions and subsequent analyses (supplemental
Figure 5) are described in supplemental Materials and methods.
Gene expression analysis by RNA-seq
Ten thousand cells of the indicated phenotypes were double sorted
into phosphate-buffered saline with 0.1% bovine serum albumin.
Cells were pelleted by centrifugation and resuspended in RLT-plus
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RNA lysis buffer (Qiagen). RNA was isolated with RNAeasy micro-
plus columns (Qiagen). RNA sequencing (RNA-seq) libraries were
generated with Clontech SMRTr kits, and sequencing was
performed on a HiSeq3000. Sequences were aligned to the
mouse genome (Ensembl release 76 top-level assembly) using
STAR version 2.0.4b.42 The sequence for human MLL-ENL was
included in the alignment. Linear modeling (limma/voom) was used
to compare gene expression across samples. False discovery rates
were calculated using the Benjamini and Hochberg method.43
Results
MLL-ENL initiates AML more efficiently in fetal/
neonatal progenitors than in juvenile/
adult progenitors
We used a previously described, tetracycline-regulated MLL-ENL
transgene (Col1a1TetO_MLL-ENL)36 to test whether the efficiency of
MLL-ENL mediated leukemia initiation changes with age. We
crossedCol1a1TetO_MLL-ENLmice with Vav1-Cre and Rosa26-loxP-
stop-loxP-tet-transactivator (RosaLSL-tTA) mice (Figure 1A). The
resulting mice (hereafter called tet-OFF-MLL-ENL) expressedMLL-
ENL specifically in hematopoietic cells beginning at embryonic day
10.5 (E10.5) in the absence of doxycycline, concordant with the
onset of Vav1-Cre expression.44 To suppress MLL-ENL expression
until later ages, we fed mothers, and later the pups, doxycycline
chow until postnatal day 0 (P0), P21, or 8 weeks after birth. These
time points encompassed fetal (E10.5), neonatal (P0), juvenile
(P21), and adult (8 weeks old) stages of induction. Analysis of
Col1a1TetO_H2B-GFP reporter mice confirmed that doxycycline could
suppress transgene expression from the Col1a1 locus in nursing
neonates, and doxycycline withdrawal at birth led to induction of the
transgene within the first 3 weeks of life (supplemental Figure 1A-B)
We observed differences in the penetrance and latency of leukemia
formation when we induced MLL-ENL expression at different ages
(Figure 1B). When MLL-ENL was induced at E10.5, a majority of
mice developed AML, though the latency varied considerably, and
some mice did not develop AML until almost 1 year later. When
MLL-ENL was induced at P0, all mice died of AML, and almost all
deaths occurred between 3 and 4 months after birth. When MLL-
ENL was induced at P21 or 8 weeks after birth, a majority of mice
survived for .1 year without developing signs of illness. All of the
moribund mice had AML based on expression of myeloid markers
Gr1 and CD11b (Figure 1C), the absence of lymphoid markers
(data not shown), and an abundance of blasts in the bone marrow
(Figure 1D). Mice that survived for .1 year without illness had only
slightly enlarged spleens (supplemental Figure 2A). There was mild
hypercellularity within the red pulp, but follicles were evident, and
there was no evidence of AML, in contrast to spleens from
moribund mice (supplemental Figure 2B-D).
We evaluated expression of theMLL-ENL transgene by RNA-seq to
confirm that it was expressed in older mice after adult induction.
MLL-ENL transcript levels were similar to endogenous Mll1 in both
10-week-old and 14-month-old HPCs and pre–granulocyte-
monocyte progenitors (pGMs) after fetal and adult induction,
respectively (Figure 1E). However, the transcript was not induced
immediately after doxycycline withdrawal in 8-week-old adult
mice. At 5 weeks after doxycycline withdrawal (13 weeks old),
MLL-ENL transcript levels were low in HPCs relative to untreatedmice
(supplemental Figure 2E). By 4 months after doxycycline withdrawal,
MLL-ENL transcript levels were similar to levels observed in untreated
mice, and they persisted 12 months later (supplemental Figure 2E).
Unfortunately, we could not detect MLL-ENL protein levels by western
blot, even in AML cells, so we were unable to assess whether protein
expression changed with age (supplemental Figure 2F). Nevertheless,
AML initiation was most efficient when the MLL-ENL transgene was
induced in neonatal progenitors.
We next tested whether transient inactivation of MLL-ENL in
neonatal mice could suppress AML initiation. We administered either
normal or doxycycline-containing chow to nursing mothers beginning
at P0 (Figure 2A). Doxycycline treatments were discontinued after 4
weeks. As in the initial experiment, sustained MLL-ENL expression
caused most of the mice to die of AML (Figure 2B). In contrast, a 4-
week pulse of doxycycline was sufficient to prevent AML in 15 of 17
mice tested (Figure 2B). The survivors had normal spleen sizes, normal
blood counts, and normal bone marrow morphology even at 1 year
after birth (Figure 2C-G). Thus, MLL-ENL–expressing fetal/neonatal
progenitors can lose leukemogenic potential if the mutation is
suppressed, even transiently, after birth.
MLL-ENL depletes fetal, but not adult, HSCs and HPCs, and it
induces age- and cell-type–specific changes in gene expression
The age-specific effects of MLL-ENL on AML initiation raised
the question of whether the mutation also has age-specific effects
on preleukemic HSCs and HPCs. We measured HSC
(CD1501CD482Lineage2Sca11c-kit1), HPC (CD150-CD481Lineage-
Sca11c-kit1), pGM (Lineage2Sca12c-kit1CD1502CD1052CD16/322),
and granulocyte-monocyte progenitor (GMPs;
Lineage2Sca12c-kit1CD1502CD1052CD16/321) numbers
after fetal (E10.5) and adult (8 week) MLL-ENL induction
(supplemental Figure 3A).45 Fetal MLL-ENL induction caused
HSC depletion at P0 that persisted at 10 weeks after birth
(Figure 3A). HPCs were also depleted in 10-week-old mice after
fetal induction (Figure 3B). These phenotypes were consis-
tent with prior observations showing that MLL-ENL impairs
HSC function,36 and they were not observed in P0 mice that
were exposed to doxycycline via their mothers (supplemental
Figure 3B-E). Adult MLL-ENL induction did not cause HSC or
HPC depletion (Figure 3A-B). Instead, it led to a modest but
significant increase in HSC numbers at 4 and 12 months after
doxycycline withdrawal (Figure 3A). pGM and GMP numbers
were not significantly altered by MLL-ENL at either age (data not
shown). BrdU incorporation assays revealed a potential expla-
nation for why MLL-ENL–expressing HSCs and HPCs were
depleted in neonatal mice. MLL-ENL impaired both HSC and
HPC proliferation in E18.5 fetal mice, consistent with prior
observations,36 but proliferation rates were similar to controls in
10-week-old adult mice (Figure 3C; supplemental Figure 4A-D).
Thus, MLL-ENL–dependent changes in HSC and HPC fate are
age specific.
We next tested whether MLL-ENL has age-specific effects on
gene expression. We performed RNA-seq on HPCs, pGMs, and
GMPs that were isolated from control and MLL-ENL–expressing
mice. After fetal MLL-ENL induction, we observed widespread
changes in gene expression at P0 (Figure 4A,C). Differentially
expressed transcripts included known MLL-ENL targets, such as
Hoxa9, Hoxa10, andMecom, and the HOXA9 target Igf1 (Figure
4D-G; supplemental Table 1). The expression changes were
more extensive in neonatal HPCs than in neonatal pGMs or
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GMPs (Figure 4A). Transcriptional changes were also far
more extensive in P0 HPCs than in 10-week-old HPCs
(Figure 4A,C). After adult MLL-ENL induction, the only differentially
expressed transcript was MLL-ENL itself (Figure 4B). Thus, the
transcriptomes of MLL-ENL–expressing progenitors change
with age.
Our data suggest that there may be a barrier to MLL-ENL target
gene expression in adult progenitors that could be overcome simply
by increasing transgene expression. To increase MLL-ENL trans-
gene expression, we generated mice that were homozygous, rather
than heterozygous, for the Col1a1TetO_MLL-ENL allele. RNA-seq
confirmed that, on average, these mice expressed MLL-ENL at
approximately twice the level observed in heterozygous HPCs,
pGMs and GMPs (Figure 5A). Homozygous Tet-OFF-MLL-ENL
mice had significant reductions in HSC and HPC populations at
10 weeks after birth, though pGM and GMP numbers were not
significantly different from littermate Vav1-Cre-negative control
mice (Figure 5B-E). Gene expression changes were more extensive
in homozygous transgenic adult HPCs, pGMs and GMPs (Figure
5F-H; supplemental Table 1), but the number of differentially
expressed genes was still small relative to the changes observed in
heterozygous neonatal HPCs (Figure 5I-J). Of note, none of
these mice received doxycycline, so age, rather than doxycycline
clearance rates, accounted for temporal changes in MLL-ENL
target gene expression. The data show that neonatal HPCs are far
more competent to activate MLL-ENL target genes than adult
HPCs, and this effect can be offset, but only partially, by doubling
MLL-ENL expression levels.
Transplanted adult progenitors are highly competent
to initiate MLL-ENL driven AML
Our data show that as hematopoietic progenitors transition from
neonatal to adult states, they become less efficient at initiating AML.
However, prior work has demonstrated highly penetrant AML
formation in recipients of transplanted adult, MLL-ENL–expressing
HPCs, pGMs, and GMPs.36 This raised the question of whether
transplantation enhances the ability of adult progenitors to initiate
AML. To test this possibility, we induced MLL-ENL at 8 weeks after
birth, as in previous cohorts (Figure 6A). Four months later, we
transplanted 300000 MLL-ENL-expressing whole bone marrow
cells and 300000 wild-type CD45.1 competitor cells into lethally
irradiated CD45.1 mice. All recipient mice exhibited multilineage
































































Figure 1. MLL-ENL initiates AML most efficiently when it is induced in neonates. (A) Overview of the strategy for inducing MLL-ENL at E10.5, P0, and 3 weeks and
8 weeks after birth. (B) Kaplan-Meier survival curves for mice after MLL-ENL induction at the indicated ages. **P , .01, ***P , .0001 relative to induction at 8 weeks after
birth. #P , .0001 for P0 relative to E10.5 induction. Survival curves were compared with the log-rank test. Group sizes are indicated. (C) Representative flow plot for AML
specimens from Tet-OFF-MLL-ENL mice. (D) Representative AML cytospin. Scale bar indicates 100 mM. (E) Expression of the MLL-ENL transcript by RNA-seq after induction
at E10.5. Reads from HPCs and pGMs were mapped to the human MLL-ENL sequence for the indicated induction ages and genotypes. Reads per kilobase of transcript per
million mapped reads values from each sample were normalized to one allele of endogenous Mll1.
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donor engraftment at 4 weeks posttransplant (Figure 6B). CD45.2
peripheral blood chimerism was somewhat higher in recipients
of MLL-ENL–expressing marrow than in recipients of Vav1-
Cre–negative control bone marrow. By 3 months posttransplant,
the recipient mice began developing AML, and all recipient mice
ultimately died (Figure 6C). We repeated the transplantation assays
by sorting and transplanting 3000 HPCs or 3000 pGMs so that we
could ascertain a cell of origin, as in the prior study by Ugale et al.36
All recipients developed AML within 120 days after transplantation
(Figure 6D). Other stressors, such as single doses of 5-fluorouracil
or a 1-week course of polyinosine:polycytosine did not stimulate
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Figure 2. Transient suppression of MLL-ENL in neonates prevents AML in most mice. (A) Overview of experimental design. (B) Kaplan-Meier survival curves for Tet-
OFF-MLL-ENL mice after neonatal suppression of the transgene. The P value is indicated and reflects a comparison of mice that received a 4-week doxycycline (Dox) pulse,
beginning at P0, to mice that did not receive doxycycline. Group sizes are indicated. Survival curves were compared by the log-rank test. (C-F) Spleen weights, white blood cell
(WBC) counts, and hemoglobin (Hgb) and platelet counts for mice that survived for .1 year after transient MLL-ENL suppression. All mice were euthanized ;12 months after
birth. (G) Representative bone marrow cytospins for mice that developed AML, in the absence of doxycycline, and mice that survived for .1 year after transient MLL-ENL
































































Figure 3. MLL-ENL depletes HSC and HPC numbers when it is induced in fetal, but not adult, mice. (A-B) HSC and HPC numbers in P0 liver (n 5 15-19) or 10-
week-old bone marrow (n 5 10-12) after fetal MLL-ENL induction or in 6-month-old bone marrow (n 5 6 per genotype) or 14-month-old bone marrow (n 5 10-11) after adult
MLL-ENL induction. Bone marrow cell numbers reflect 2 hindlimbs (tibias and femurs). (C) Twenty-four-hour HSC and HPC BrdU incorporation percentages were measured in
E18.5 livers (n 5 5-7) or 10-week-old bone marrow (n 5 7 per genotype) after fetal MLL-ENL induction. For all panels, error bars indicate standard deviations. **P , .01,
***P , .001 for Tet-OFF-MLL-ENL relative to controls. Groups were compared by the 2-tailed Student t test.
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HPCs expressed lower rather than higher levels of MLL-ENL target
genes when they were stressed by ex vivo culture (supplemental
Figure 5B). Thus, transplantation stress can mitigate the barrier to
AML initiation in adulthood, but other stressors may not, at least
when they are transiently applied.
The fetal master regulator, Lin28b, suppresses
MLL-ENL–driven AML initiation
The finding that MLL-ENL initiates AML more efficiently in fetal/
neonatal progenitors than in adult progenitors raised the question of
whether fetal-specific genes could accelerate leukemogenesis.
Consistent with this possibility, 3 previously described fetal HSC
regulators, Lin28b, Hmga2, and Igf2bp2, were hyperactivated by
MLL-ENL in neonatal, but not adult, HPCs (Figure 7A-C). Lin28b
encodes a fetal master regulator that has been shown to promote
self-renewal and fetal lineage priming when it is expressed in adult
HSCs.33,34,46,47 It enhances Hmga2 and Igfbp2 expression by
inhibiting let-7 family microRNAs.33 These genes potentially interact
with MLL-ENL to promote AML initiation.
To test whether Lin28b could accelerate MLL-ENL–driven leuke-
mogenesis, we generated mice to express both MLL-ENL and
Lin28b transgenes from the Col1a1 allele (Vav1-Cre; Rosa26LSL-tTA;
Col1a1tetO_MLL-ENL/tetO_Lin28b). We induced MLL-ENL and Lin28b
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Figure 4. MLL-ENL induces changes in gene expression more efficiently in neonatal HPCs than in older or more committed progenitors. (A) Volcano plots
show genes that are significantly induced (red) or significantly repressed (green) in HPCs, pGMs, or GMPs at P0, or in 10-week-old HPCs, after fetal MLL-ENL induction. The
MLL-ENL transcript was mapped, and expression is indicated as a blue data point. RNA-seq data were analyzed, and adjusted (adj.) P values were calculated, as indicated in
"Materials and methods." Genes that changed with an adjusted P , .05 were considered significantly differentially expressed. (B) Volcano plots showing a lack of differential
gene expression after adult MLL-ENL induction. The panels indicate gene expression 6-month-old or 14-month-old mice (4 months or 12 months after doxycycline withdrawal).
MLL-ENL was expressed at these ages as indicated by the blue dots. (C) Venn diagrams comparing the number of genes for the indicated cell types and ages that showed
significantly increased expression and a fold change .2. Data reflect fetal MLL-ENL induction. FDR, false discovery rate. (D-G) Reads per kilobase of transcript per million
mapped reads (RPKM) values for Hoxa9, Hoxa10, Mecom, and Igf1 at the indicated ages after fetal MLL-ENL induction. Error bars indicate standard deviation. ***Adjusted
P , .001. For all groups, n 5 3 to 4 independent biological replicates.
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Lin28b expression naturally declines,32,33 and we monitored
survival. As in the previous analyses, almost all MLL-ENL–
expressing mice died of AML within 130 days (Figure 7D).
However, a majority of compound MLL-ENL/Lin28b-expressing
mice unexpectedly survived for .300 days (Figure 7D). Most
had only slightly enlarged spleens and normal HSC and HPC
numbers at 1 year after MLL-ENL and Lin28b induction,
indicating that coexpression of MLL-ENL and Lin28b was
not inherently toxic to hematopoietic progenitors (Figure
7E-G). A few mice in the MLL-ENL/Lin28b–expressing cohort
did become moribund, and they had markedly enlarged spleens
(Figure 7E). However, they did not have AML. Instead, the
spleens were infiltrated with malignant CD31 T cells (Figure 7H-I).
T-cell lymphomas have been previously observed in transgenic
Vav1-Lin28b mice.48 Thus, the lymphomas that arose in MLL-
ENL/Lin28b–expressing mice were likely caused by Lin28b
rather than MLL-ENL.
We tested whether other fetal gene products can similarly suppress
AML initiation. We transduced E16.5 Tet-OFF-MLL-ENL progen-
itors (Lineage2c-kit1) with lentiviruses to express enhanced green
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Figure 5. Increased MLL-ENL expression partially overcomes the barrier to target gene activation and repression in adult progenitors. (A) MLL-ENL transcript
levels in Col1a1TetO_MLL-ENL heterozygous or homozygous mice. Transcript expression was normalized to endogenous Mll1 in each sample, as in Figure 1E. (B-E) HSC, HPC,
pGM, and GMP numbers in 10-week-old, homozygous Tet-OFF-MLL-ENL mice after fetal induction. Error bars indicate standard deviations. n 5 5 to 8, *P , .05, **P , .01;
groups were compared with the 2-tailed Student t test. (F-H) Volcano plots show genes that are significantly induced (red) or significantly repressed (green) in HPCs, pGMs,
or GMPs in 10-week-old mice that are homozygous for the Col1a1TetO_MLL-ENL allele. The MLL-ENL transcript was mapped, and expression is indicated as a blue data point.
Adjusted P values were calculated as indicated in "Materials and methods." (I-J) Numbers of unique genes that were significantly induced or repressed with a fold change .2
in P0 mice with a heterozygous Col1a1TetO_MLL-ENL allele, as compared with adult mice with a homozygous Col1a1TetO_MLL-ENL allele. Changes in gene expression were far
more extensive in neonatal HPCs than at other time points or in other cell types, despite the presence of only a single MLL-ENL transgene. For all groups, n 5 4 independent
biological replicates. For panels B-E, Ctl indicates control and ME indicates Tet-OFF-MLL-ENL genotypes.
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IGFBP3, and GEM)32 fused to a 2A-enhanced green fluorescent
protein reporter. The transduced cells were transplanted into
lethally irradiated recipients (20 000/recipient) along with 300000
uninfected bone marrow cells. Recipients were monitored until they
became moribund. Lin28b expression significantly extended
survival of recipient mice (supplemental Figure 6A). In contrast,
none of the other fetal genes extended survival. Thus, Lin28b can
suppress AML initiation in a transplantation model, just as it does in
Tet-OFF-MLL-ENL/Lin28b mice, and this phenotype appears to be
relatively specific to Lin28b.
In contrast to its effect on AML initiation, Lin28b did not impair
growth of fully transformed AML cells, at least not in vitro. We
transduced MOLM14 cells (which express an MLL rearrangement)
and K562 cells (which do not) with control or Lin28b-expressing
lentiviruses. Transduced cells had no growth advantage or disadvan-
tage relative to nontransduced cells (supplemental Figure 6B).
Altogether, the data suggest that Lin28b may help prevent AML
initiation in fetal progenitors rather than potentiating transformation. In
this model, naturally declining Lin28b levels could enhance AML
initiation efficiency for a period of time after birth (Figure 7M). This
model may explain why AML formation was more penetrant whenMLL-
ENL was induced at P0 than at E10.5 (Figure 1B).
Discussion
MLL fusion proteins are potent oncoproteins that drive leukemo-
genesis in infants with very few cooperating mutations.3 This
suggests that fetal or neonatal hematopoietic progenitors may be
exquisitely sensitive to MLL fusion proteins. Our data confirm that
the efficiency of MLL-ENL-driven AML initiation changes with age,
and it peaks shortly after birth. This period correlates with the age at
which MLL-ENL most effectively alters gene expression. Indeed,
critical effectors of leukemogenesis, such as Hoxa9, Hoxa10, and
Mecom, are induced more highly in neonatal progenitors than in
adult progenitors. Our data suggest that developmental context
plays an important role in shaping the genetic landscapes of MLL-
rearranged leukemias. Fewer cooperating mutations are observed
in infant leukemias because neonatal progenitors are inherently
more competent to transform.
It is not clear why adult progenitors respond differently toMLL-ENL
expression than neonatal progenitors. One possible explanation is
that there are epigenetic barriers to target gene expression in adult
HPCs, pGMs, and GMPs that do not exist to the same degree in
neonatal progenitors. A second possibility is that the MLL-ENL
protein may be less stable in adult progenitors than in neonatal
progenitors. A third possibility is that yet-to-be identified fetal/
neonatal transcription factors collaborate with MLL-ENL to en-
hance target gene expression and initiate leukemogenesis.
These mechanisms are not mutually exclusive, but they all point to
a developmental barrier that can be reversed by stress, given the
effects of transplantation on leukemogenesis (Figure 6). It should be
noted that an inducible MLL-AF9 transgenic mouse has been
shown to develop AML after adult transgene induction.26 This
difference could reflect different levels of transgene expression in
the different models or important functional differences between
MLL-ENL and MLL-AF9. Additional studies are needed to un-
derstand how normal temporal changes in HSC, HPC, and pGM
epigenomes might alter transcriptional responses to MLL-ENL, how
barriers to transformation can be overcome by stress or in-
flammation, and whether the developmental barriers are relevant
to other pediatric AML fusion proteins, such as MLL-AF9.
The link between development and leukemia initiation is potentially
clinically important. It raises the possibility of identifying patients
who are at high risk for developing infant leukemia and temporarily
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Figure 6. Transplanted HPCs and pGMs give rise to AML after adult MLL-ENL induction. (A) Overview of experiment timeline. (B) Percentage of donor (CD45.2)
peripheral blood myeloid cells (CD11b1Gr11), B cells (B2201), and T cells (CD31) at 4 weeks after transplantation. *P , .05, **P , .01; groups were compared with the
2-tailed Student t test. (C) Kaplan-Meier survival curves for mice transplanted with control or MLL-ENL–expressing bone marrow. (D) Survival curves for a second cohort of
MLL-ENL–expressing mice transplanted with 300 000 whole bone marrow cells or 3000 HPCs or pGMs. Group sizes are indicated. Survival curves were compared with the
log-rank test.
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that prophylaxis may not be practical: inhibitors of DOT1L and MLL
fusion complexes are still in early-phase or preclinical trials,49,50 the
pharmacokinetics of currently available drugs likely precludes
prophylactic use,49 and the sensitivity/specificity of translocations
identified in newborn blood remains unclear. Furthermore, addi-
tional studies are needed to test whether infection or inflammation
can potentiate MLL-ENL–driven leukemogenesis at later stages of
development, as this would undermine any protection afforded by
age. In principle, if the technical difficulties can be navigated, then
transient suppression of the MLL fusion protein could allow children
to age out of their window of peak leukemia susceptibility.
In addition to demonstrating a link between developmental context
and AML initiation, our studies have shown that Lin28b can
antagonize rather than facilitate AML initiation. This was surprising,
because human LIN28B is generally thought to promote pediatric
tumor growth (eg, neuroblastoma, hepatoblastoma, and Wilm
tumor)51-53 rather than suppress transformation, and Lin28b was
upregulated by MLL-ENL in neonates. Nevertheless, the differences
between Lin28b-expressing and nonexpressing mice were striking,
and Lin28b-expressing mice did not develop AML (Figure 7G). This
finding was consistent with data showing that let-7 microRNAs
are elevated in poor prognosis pediatric AML.2 The human data
suggest that LIN28B may function as a tumor suppressor in early
childhood AML by suppressing let-7 expression. Since Lin28b
had no effect on fully transformed AML cells (supplemental
Figure 6B), it likely modulates early steps of AML initiation,
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Figure 7. Lin28b suppresses MLL-ENL–driven AML. (A-C) Lin28b, Hmga2 and Igf2bp2 were hyper-activated in MLL-ENL expressing neonatal, but not adult, HPCs.
***Adjusted P , .001. (D) Survival of Tet-OFF-MLL-ENL and Tet-OFF-MLL-ENL/Lin28b mice after neonatal transgene induction. Curves were compared by the log-rank test.
(E-G) Spleen weight and HSC and HPC numbers in surviving Tet-OFF-MLL-ENL/Lin28b after they were euthanized at .1 year old. (H-I) Representative spleen histology and
CD3 expression in control mice or Tet-OFF-MLL-ENL/Lin28b mice that became moribund. Scale bars indicate 100 mM (large panels) or 40 mM (insets). (J) MLL-ENL initiates
AML most efficiently when it is induced during the neonatal stage of development. Lin28b might protect against AML initiation in utero. At later stages of development,
MLL-ENL fails to activate target genes as efficiently as it does in neonates.
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fates that do not support efficient transformation, such as
megakaryocytic-erythroid progenitors.36,47,54 Additional studies
are needed to test whether Lin28b deletion can acceler-
ate leukemogenesis, but our findings raise the possibility of
manipulating developmental programs to treat or prevent pediatric
malignancies.
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